Stockpolly
Search
BRVE · NASDAQ · Biotechnology

Braveheart Bio (BRVE)

Developing BHB-1893, an oral cardiac myosin inhibitor for hypertrophic cardiomyopathy.

$26.77
At close+0.49 (+1.86%)
Watchlist

Something off on this page? Send us feedback.

Breakdown13F · 13D/G · Form 4

Insiders7 holders · as of Aug 7, 202613.77%9.73M shares
Strategic holders3 holders · as of Aug 18, 202644.21%31.24M shares
Otherremainder42.02%29.69M shares

70.65M company shares as of Aug 22, 2026 · holders as of their latest filing

Top shareholders13F · 13D/G · Form 4

HolderStakeSharesEvidence
Orbimed Advisors LLCStrategicdirector, 10 percent owner
17.23%12.18M13Dfiled Aug 18, 2026 ↗
Forbion Growth Opportunities Fund III Cooperatief U.A.1Strategic10 percent owner
16.48%11.64MForm 4filed Aug 7, 2026 ↗
Jiangsu Hengrui Pharmaceuticals Co., Ltd.Strategic10 percent owner
10.50%7.42MForm 4filed Aug 10, 2026 ↗
Travis MurdochInsiderdirector, officer: CEO and President
8.89%6.28MForm 4filed Aug 7, 2026 ↗
Jason V. ColomaInsiderdirector
1.29%913,242Form 4filed Aug 6, 2026 ↗
David I. MalekInsiderdirector
1.09%773,571Form 4filed Aug 7, 2026 ↗
Christopher ViehbacherInsiderdirector
1.08%759,857Form 4filed Aug 7, 2026 ↗
James Paul RickeyInsiderofficer: Chief Financial Officer
0.87%612,251Form 4filed Aug 7, 2026 ↗
Michele A. AndersonInsiderofficer: Chief Development Officer
0.47%332,161Form 4filed Aug 7, 2026 ↗
David Charles LubnerInsiderdirector
0.08%55,555Form 4filed Aug 7, 2026 ↗
AH Bio Fund IV, L.P.2Strategic10 percent owner
0.00%0Form 4filed Aug 11, 2026 ↗
Vineeta Agarwala3Insiderdirector
0.00%0Form 4filed Aug 14, 2026 ↗
Erez Chimovits4Insiderdirector, 10 percent owner
0.00%0Form 4filed Aug 11, 2026 ↗
Frazier Life Sciences Public Fund, L.P.Institution
—5.50% of class, as filed—13Gfiled Aug 14, 2026 ↗
  1. Forbion Growth Opportunities Fund III Cooperatief U.A. reports a block also reported by AH Bio Fund IV, L.P.; it is counted once, under AH Bio Fund IV, L.P.
  2. AH Bio Fund IV, L.P. reports a block also reported by Orbimed Advisors LLC; it is counted once, under Orbimed Advisors LLC.
  3. Vineeta Agarwala reports a block also reported by Orbimed Advisors LLC; it is counted once, under Orbimed Advisors LLC.
  4. Erez Chimovits reports a block also reported by Orbimed Advisors LLC; it is counted once, under Orbimed Advisors LLC.

13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report

Institutions13F

No 13F holders on record.

Ownership statements13D/G · 5% or more, as filed

Holder% of classSharesFormFiled
Orbimed Advisors LLCincl. OrbiMed Capital GP IX LLC, OrbiMed Genesis GP LLC17.20%12.18M13DAug 18, 2026 ↗
AH Bio Fund IV, L.P.incl. AH Equity Partners Bio IV, L.L.C., Marc L. Andreessen +1 more11.40%10.23M13DAug 14, 2026 ↗
Frazier Life Sciences Public Fund, L.P.5.50%4.98M13GAug 14, 2026 ↗

Insider tradesForm 4

Latest trades

DateInsiderTypeSharesAvg priceOwned after
Aug 7, 2026
AH Bio Fund IV, L.P.10 percent owner
Purchase1,100,000$18.0010,232,420
Aug 7, 2026
Erez Chimovitsdirector, 10 percent owner:
Purchase · 2 lots1,940,000$18.0011,901,826
Aug 7, 2026
Orbimed Advisors LLCdirector, 10 percent owner:
Purchase · 2 lots1,940,000$18.0011,901,826
Aug 7, 2026
David Charles Lubnerdirector
Purchase55,555$18.0055,555
Aug 7, 2026
Travis Murdochdirector, officer: CEO and President
Purchase83,333$18.002,940,670
Aug 7, 2026
Michele A. Andersonofficer: Chief Development Officer
Purchase1,111$18.00332,161
Aug 7, 2026
David I. Malekdirector
Purchase4,166$18.00533,845
Aug 7, 2026
Christopher Viehbacherdirector
Purchase83,333$18.00609,519
Aug 7, 2026
James Paul Rickeyofficer: Chief Financial Officer
Purchase27,777$18.00520,927
Aug 7, 2026
Forbion Growth Opportunities Fund III Cooperatief U.A.10 percent owner
Purchase · 2 lots3,600,000$18.0021,826,024

CongressHouse and Senate disclosures

Not reported.